Svennilson Peter
Follow13F filer, CIK 1606074, SAN FRANCISCO, CA
Svennilson Peter reported $1,225,585,000 across 7 holdings for the quarter ended 2020-09-30, in a 13F-HR filed 2020-11-04.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-20-010814
- Period
- 2020-09-30
- Reported value
- $1.23B
- Holdings
- 7
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 1
Stakes and trades reported after 2020-09-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
Accepted , ingested - TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| NRIXnew | +6,755,881 | $236M |
| NGM BIOPHARMACEUTICALS INCadded | +310,954 | $4.95M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| RCUSexited | -1,767,676 | -$43.7M |
| RAPT THERAPEUTICS INCreduced | -1,146,654 | -$36.9M |
| GRITSTONE BIO INCreduced | -831,452 | -$2.2M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2020
Share positions as resolved from 13F-HR 0000950123-20-010814, largest first. % of portfolio is the value over $1,225,585,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 18,017,932 | $287M | 23.39% | +310,954 | |||
| RVMDREVOLUTION MEDICINES INC | 7,977,384 | $278M | 22.65% | 0 | Timeline | ||
| NRIXNURIX THERAPEUTICS INC | 6,755,881 | $236M | 19.24% | new | Timeline | ||
| RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC | 5,630,497 | $181M | 14.79% | -1,146,654 | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 6,051,376 | $123M | 10% | 0 | |||
| ORICORIC PHARMACEUTICALS INC | 4,768,181 | $119M | 9.73% | 0 | Timeline | ||
| GRITSTONE BIO INCGRITSTONE BIO INC | 869,493 | $2.3M | 0.19% | -831,452 |
Sold out in Q3 2020
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| RCUSARCUS BIOSCIENCES INC | 1,767,676 | $43.7M | shares |
How Q3 2020 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-20-010814 | base | 2020-11-04 | acceptance time not in the bulk data set |